Facial psoriasis linked to reduced QoL, but ixekizumab helps

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Facial psoriasis is associated with reduced health-related QoL (HRQoL), while ixekizumab (IXE) treatment is associated with facial clearance.

Why this matters

  • Combined results of UNCOVER-2 and UNCOVER-3 trials suggest the efficacy of ixekizumab for facial psoriasis, which is linked to QoL.

Key results

  • Clearance of facial psoriasis was associated with improved Dermatology Life Quality Index 0-1 response (P<.01 for ixe every wk and psoriasis skin appearance bothersomeness score compared with not achieving facial clearance.>
  • IXE treatment was associated with increased facial clearance (84.1% for every 2 wk, 78.7% for every 4 wk) compared with etanercept (67.9%; P<.001 vs ixe wk and p every placebo>

Study design

  • 2570 patients with moderate-to-severe psoriasis, 1133 with facial psoriasis and 1437 without, were randomly assigned to placebo, etanercept twice-weekly, or ixekizumab every 4 wk or every 2 wk and analyzed for outcomes at 12 wk.
  • Combined results of 2 phase 3 multicenter, randomized, double-blind, placebo-controlled, active-comparator trials.
  • Funding: Eli Lilly and Company.

Limitations

  • No measure of site or severity of facial psoriasis.